Abstract 1882: DXC024, a novel anti-TROP2/EGFR bispecific antibody and tubulysin conjugate, for targeted treatment of highly TROP2- or EGFR-expressing tumors
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-1882
Abstract: Antibody drug conjugates (ADCs) which combine the precision of targeted therapy with the cytotoxic effects of chemotherapy have become a promising drug class in cancer therapy. Epidermal growth factor receptor (EGFR) is overexpressed in a… read more here.
Keywords: egfr; targeted treatment; dxc024; anti trop2 ... See more keywords